Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roser Velasco

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patientsRoser Velasco, Jordi Bruna, Chiara Briani, et al.
Cancer|July 13, 2012
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancerAndreas A Argyriou, Guido Cavaletti, Chiara Briani, et al.
Anti-Cancer Drugs|December 17, 2020
Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experienceRoser Velasco, Sarah Besora, Andreas A Argyriou, et al.
Journal of the Peripheral Nervous System : JPNS|January 14, 2015
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up studyChiara Briani, Andreas A Argyriou, Cristina Izquierdo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 30, 2018
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nervePaola Alberti, Emanuela Rossi, Andreas A Argyriou, et al.
European Journal of Neurology|September 16, 2024
Repurposing chemotherapy-induced peripheral neuropathy gradingRoser Velasco, Andreas A Argyriou, David R Cornblath, et al.
Expert Review of Neurotherapeutics|December 13, 2021
Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinionSusanna B Park, Stefano Tamburin, Angelo Schenone, et al.
Neuro-Oncology|January 13, 2016
An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cellsMaría Sánchez-Osuna, Laura Martínez-Escardó, Carla Granados-Colomina, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 20, 2017
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical TrialJordi Bruna, Sebastián Videla, Andreas A Argyriou, et al.
Cancer|July 4, 2013
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter studyAndreas A Argyriou, Guido Cavaletti, Anna Antonacopoulou, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patientsRoser Velasco, Jordi Bruna, Chiara Briani, et al.
Cancer|July 13, 2012
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancerAndreas A Argyriou, Guido Cavaletti, Chiara Briani, et al.
Anti-Cancer Drugs|December 17, 2020
Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experienceRoser Velasco, Sarah Besora, Andreas A Argyriou, et al.
Journal of the Peripheral Nervous System : JPNS|January 14, 2015
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up studyChiara Briani, Andreas A Argyriou, Cristina Izquierdo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 30, 2018
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nervePaola Alberti, Emanuela Rossi, Andreas A Argyriou, et al.
European Journal of Neurology|September 16, 2024
Repurposing chemotherapy-induced peripheral neuropathy gradingRoser Velasco, Andreas A Argyriou, David R Cornblath, et al.
Expert Review of Neurotherapeutics|December 13, 2021
Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinionSusanna B Park, Stefano Tamburin, Angelo Schenone, et al.
Neuro-Oncology|January 13, 2016
An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cellsMaría Sánchez-Osuna, Laura Martínez-Escardó, Carla Granados-Colomina, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 20, 2017
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical TrialJordi Bruna, Sebastián Videla, Andreas A Argyriou, et al.
Cancer|July 4, 2013
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter studyAndreas A Argyriou, Guido Cavaletti, Anna Antonacopoulou, et al.
Pageof 6